Legacy Pharma Drug Patent Portfolio
Legacy Pharma owns 4 orange book drugs protected by 35 US patents Given below is the list of Legacy Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10188637 | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same | 28 Mar, 2037 | Active |
| US8778947 | Methods of administering pirfenidone therapy | 30 Aug, 2033 | Active |
| US10166205 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US10166206 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US10695303 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US10729667 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US8778365 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US9161914 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US7816383 | Methods of administering pirfenidone therapy | 08 Jan, 2030 | Active |
| US7910610 | Methods of administering pirfenidone therapy | 08 Jan, 2030 | Active |
| US8013002 | Methods of administering pirfenidone therapy | 08 Jan, 2030 | Active |
| US8084475 | Pirfenidone therapy and inducers of cytochrome P450 | 08 Jan, 2030 | Active |
| US8318780 | Methods of administering pirfenidone therapy | 08 Jan, 2030 | Active |
| US8648098 | Pirfenidone therapy and inducers of cytochrome P450 | 08 Jan, 2030 | Active |
| US8754109 | Pirfenidone therapy and inducers of cytochrome P450 | 08 Jan, 2030 | Active |
| US7566729 | Modifying pirfenidone treatment for patients with atypical liver function | 22 Apr, 2029 | Active |
| US7635707 | Pirfenidone treatment for patients with atypical liver function | 22 Apr, 2029 | Active |
| US8592462 | Pirfenidone treatment for patients with atypical liver function | 22 Apr, 2029 | Active |
| US8609701 | Pirfenidone treatment for patients with atypical liver function | 22 Apr, 2029 | Active |
| US8658663 | Method of treating thermoregulatory disfunction with paroxetine | 06 Apr, 2029 | Active |
| US8383150 | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients | 10 May, 2028 | Active |
| US7696236 | Method of providing pirfenidone therapy to a patient | 18 Dec, 2027 | Active |
| US7696326 | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof | 18 Dec, 2027 | Active |
| US7767700 | Method of providing pirfenidone therapy to a patient | 18 Dec, 2027 | Active |
| US8420674 | Method of providing pirfenidone therapy to a patient | 18 Dec, 2027 | Active |
| US7767225 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | 22 Sep, 2026 | Active |
| US7988994 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | 22 Sep, 2026 | Active |
| US8753679 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | 22 Sep, 2026 | Active |
| US8946251 | Method of treating thermoregulatory dysfunction with paroxetine | 04 Aug, 2026 | Active |
| US9393237 | Method of treating thermoregulatory dysfunction with paroxetine | 04 Aug, 2026 | Active |
| US7598271 | Crystalline paroxetine methane sulfonate | 04 May, 2025 | Expired |
| US9561217 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone | 25 Jan, 2022 | Expired |
| US6284770 | Medicaments for the treatment of non-constipated female irritable bowel syndrome | 05 Oct, 2018 | Expired |
| US5874447 | 4-Phenylpiperidine compounds for treating depression | 10 Jun, 2017 | Expired |
| US5360800 | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives | 13 Jan, 2013 | Expired |
Latest Legal Activities on Legacy Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Legacy Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 May, 2024 | US8318780 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 17 Jan, 2024 | US10729667 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 03 Jan, 2024 | US9393237 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 13 Dec, 2023 | US10695303 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Jun, 2023 | US8084475 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Apr, 2023 | US9161914 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Feb, 2023 | US8013002 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Jan, 2023 | US7988994 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Sep, 2022 | US7910610 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 20 Jul, 2022 | US8946251 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Jul, 2022 | US10188637 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Jun, 2022 | US10166206 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Jun, 2022 | US10166205 |
|
Expire Patent
Critical
| 16 May, 2022 | US7696326 |
|
Withdrawal of Application for PTE
Critical
| 20 Apr, 2022 | US8420674 |
Legacy Pharma's Drug Patent Litigations
Legacy Pharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 30, 2012, against patent number US8658663. The petitioner , challenged the validity of this patent, with Patricia Allison Tewes Richards as the respondent. Click below to track the latest information on how companies are challenging Legacy Pharma's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8658663 | January, 2012 |
Decision
(21 Oct, 2013)
| Patricia Allison Tewes Richards | |
Legacy Pharma Drug Patents' Oppositions Filed in EPO
Legacy Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 28, 2012, by Sandoz Ag. This opposition was filed on patent number EP10250379A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16151564A | Mar, 2022 | Zentiva k.s. | Granted and Under Opposition |
| EP16151564A | Mar, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP16151564A | Mar, 2022 | Generics [UK] Limited | Granted and Under Opposition |
| EP16151564A | Mar, 2022 | Aera A/S | Granted and Under Opposition |
| EP17716354A | Feb, 2022 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP13176914A | Feb, 2021 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP13176914A | Feb, 2021 | Intas Pharmaceuticals Ltd. | Granted and Under Opposition |
| EP13176914A | Feb, 2021 | Aera A/S | Granted and Under Opposition |
| EP10835207A | Feb, 2021 | Intas Pharmaceuticals Ltd. | Revoked |
| EP10835207A | Feb, 2021 | Generics [UK] Limited | Revoked |
| EP10835207A | Feb, 2021 | SANDOZ AG | Revoked |
| EP13176914A | Feb, 2021 | SANDOZ AG | Granted and Under Opposition |
| EP10835207A | Feb, 2021 | Aera A/S | Revoked |
| EP10835207A | Jan, 2021 | STADA Arzneimittel AG | Revoked |
| EP10835207A | Jan, 2021 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP13275196A | Jun, 2017 | Sandoz AG | Revoked |
| EP13275196A | Jun, 2017 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP11002040A | Jan, 2017 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP11002040A | Jan, 2017 | Sandoz AG | Revoked |
| EP12166074A | Jan, 2017 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP12166074A | Dec, 2016 | Sandoz AG | Revoked |
| EP12166074A | Dec, 2016 | ratiopharm GmbH | Revoked |
| EP11002040A | Dec, 2016 | ratiopharm GmbH | Revoked |
| EP11001414A | Jul, 2015 | Sandoz AG | Revoked |
| EP06815221A | Mar, 2015 | Dannenberger, Oliver Andre | Patent maintained as amended |
| EP10250379A | Jun, 2012 | Sandoz AG | Revoked |
Legacy Pharma's Family Patents
Legacy Pharma drugs have patent protection in a total of 47 countries. It's US patent count contributes only to 27.6% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Legacy Pharma Drug List
Given below is the complete list of Legacy Pharma's drugs and the patents protecting them.
1. Brisdelle
Brisdelle is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8658663 | Method of treating thermoregulatory disfunction with paroxetine |
06 Apr, 2029
(3 years from now)
| Active |
| US8946251 | Method of treating thermoregulatory dysfunction with paroxetine |
04 Aug, 2026
(7 months from now)
| Active |
| US9393237 | Method of treating thermoregulatory dysfunction with paroxetine |
04 Aug, 2026
(7 months from now)
| Active |
| US7598271 | Crystalline paroxetine methane sulfonate |
04 May, 2025
(7 months ago)
| Expired |
| US5874447 | 4-Phenylpiperidine compounds for treating depression |
10 Jun, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brisdelle's drug page
2. Esbriet
Esbriet is protected by 22 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10188637 | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
28 Mar, 2037
(11 years from now)
| Active |
| US8778947 | Methods of administering pirfenidone therapy |
30 Aug, 2033
(7 years from now)
| Active |
| US7816383 | Methods of administering pirfenidone therapy |
08 Jan, 2030
(4 years from now)
| Active |
| US7910610 | Methods of administering pirfenidone therapy |
08 Jan, 2030
(4 years from now)
| Active |
| US8013002 | Methods of administering pirfenidone therapy |
08 Jan, 2030
(4 years from now)
| Active |
| US8084475 | Pirfenidone therapy and inducers of cytochrome P450 |
08 Jan, 2030
(4 years from now)
| Active |
| US8318780 | Methods of administering pirfenidone therapy |
08 Jan, 2030
(4 years from now)
| Active |
| US8648098 | Pirfenidone therapy and inducers of cytochrome P450 |
08 Jan, 2030
(4 years from now)
| Active |
| US8754109 | Pirfenidone therapy and inducers of cytochrome P450 |
08 Jan, 2030
(4 years from now)
| Active |
| US7566729 | Modifying pirfenidone treatment for patients with atypical liver function |
22 Apr, 2029
(3 years from now)
| Active |
| US7635707 | Pirfenidone treatment for patients with atypical liver function |
22 Apr, 2029
(3 years from now)
| Active |
| US8592462 | Pirfenidone treatment for patients with atypical liver function |
22 Apr, 2029
(3 years from now)
| Active |
| US8609701 | Pirfenidone treatment for patients with atypical liver function |
22 Apr, 2029
(3 years from now)
| Active |
| US8383150 | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
10 May, 2028
(2 years from now)
| Active |
| US7696236 | Method of providing pirfenidone therapy to a patient |
18 Dec, 2027
(1 year, 11 months from now)
| Active |
| US7696326 | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof |
18 Dec, 2027
(1 year, 11 months from now)
| Active |
| US7767700 | Method of providing pirfenidone therapy to a patient |
18 Dec, 2027
(1 year, 11 months from now)
| Active |
| US8420674 | Method of providing pirfenidone therapy to a patient |
18 Dec, 2027
(1 year, 11 months from now)
| Active |
| US7767225 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
22 Sep, 2026
(8 months from now)
| Active |
| US7988994 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
22 Sep, 2026
(8 months from now)
| Active |
| US8753679 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
22 Sep, 2026
(8 months from now)
| Active |
| US9561217 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
25 Jan, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Esbriet's drug page
3. Lotronex
Lotronex is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6284770 | Medicaments for the treatment of non-constipated female irritable bowel syndrome |
05 Oct, 2018
(7 years ago)
| Expired |
| US5360800 | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
13 Jan, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lotronex's drug page
4. Naftin
Naftin is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10166205 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
| US10166206 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
| US10695303 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
| US10729667 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
| US8778365 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
| US9161914 | Topical compositions and methods for making and using same |
31 Jan, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Naftin's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List